Search

Your search keyword '"Knappik, Michael"' showing total 16 results
Start Over Author "Knappik, Michael"
16 results on '"Knappik, Michael"'

1. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

Author

Mocroft, Amanda, Pelchen-Matthews, Annegret, Hoy, Jennifer, Llibre, Josep M., Neesgaard, Bastian, Jaschinski, Nadine, Domingo, Pere, Rasmussen, Line Dahlerup, Günthard, Huldrych F., Surial, Bernard, Öllinger, Angela, Knappik, Michael, de Wit, Stephane, Wit, Ferdinand, Mussini, Cristina, Vehreschild, Joerg, Monforte, Antonella D’Arminio, Sonnerborg, Anders, Castagna, Antonella, Anne, Alain Volny, Vannappagari, Vani, Cohen, Cal, Greaves, Wayne, Wasmuth, Jan C., Spagnuolo, Vincenzo, and Ryom, Lene

Published
2024
Full Text
View/download PDF

2. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Hasan Hafizi, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, and van Leth, Frank

Published
2023
Full Text
View/download PDF

3. A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection

Author

Springer, David Niklas, primary, Daller, Simon, additional, Knappik, Michael, additional, Prüger, Katja, additional, Hartl, Sylvia, additional, Breyer-Kohansal, Robab, additional, Puchhammer-Stöckl, Elisabeth, additional, Aberle, Judith Helene, additional, Weseslindtner, Lukas, additional, and Breyer, Marie Kathrin, additional

Published
2024
Full Text
View/download PDF

4. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes

Author

Mocroft, Amanda, primary, Pelchen-Matthews, Annegret, additional, Hoy, Jennifer, additional, Llibre, Josep M., additional, Neesgaard, Bastian, additional, Jaschinski, Nadine, additional, Domingo, Pere, additional, Rasmussen, Line Dahlerup, additional, Günthard, Huldrych F., additional, Surial, Bernard, additional, Öllinger, Angela, additional, Knappik, Michael, additional, De Wit, Stephan, additional, Wit, Ferdinand, additional, Mussini, Cristina, additional, Vehreschild, Joerg, additional, Monforte, Antonella D’Arminio, additional, Sonnerborg, Anders, additional, Castagna, Antonella, additional, Anne, Alain Volny, additional, Vannappagari, Vani, additional, Cohen, Cal, additional, Greaves, Wayne, additional, Wasmuth, Jan C., additional, Spagnuolo, Vincenzo, additional, and Ryom, Lene, additional

Published
2023
Full Text
View/download PDF

5. Availability and costs of medicines for the treatment of tuberculosis in Europe

Author

Günther, Gunar, Guglielmetti, Lorenzo, Leu, Claude, Lange, Christoph, van Leth, Frank, Hafizi, Hasan, Khachatryan, Naira, Aroyan, Harut, Kabasakalyan, Eduard, Knappik, Michael, Skrahina, Alena, Klimuk, Dzmitry, Nikolenka, Alena, Muylle, Inge, Milanov, Vladimir, Velkovska, Desislava, Tarinska, Neli, Bachiyska, Elizabeta, Jankovic, Mateja, Pieridou, Despo, Adamide, Tonia, Nicolaou, Nicos, Vasakova, Martina, Sukholytka, Mariia, Kopeckà, Emilia, Andersen, Åse Bengård, Folkvardsen, Dorte Bek, Svensson, Erik, Danilovits, Manfred, Kummik, Tiina, Vasankari, Tuula, Fréchet-Jachym, Mathilde, Nahmiash, Audrey, Togonidze, Tamar, Avaliani, Zaza, Kinkladze, Inga, Aspindzelashvili, Rusudan, Bichashvili, Teona, Losaberidze, Gulnazi, Merabishvili, Tsitsino, Kalsdorf, Barbara, Manika, Katerina, Tsiakitzis, Karyofyllis, Bakos, Agnes, Ægisdóttir, Tinna Rán, Michelsen, Guðrún Svanhvít, Karlsdóttir, Kristín, McLaughlin, Anne-Marie, Fitzgibbon, Margaret, Chemtob, Daniel, Codecasa, Luigi R., Ferrarese, Maurizio, Torri, Stefania, Gjocaj, Majlinda, Kuksa, Liga, Davidaviciene, Edita, Wirtz, Gil, Perrin, Monique, Asciak, Analita Pace, Chesov, Dumitri, de Lange, Wiel, Akkerman, Onno, Poposka, Biljana Ilievska, Mack, Ulrich, Jensenius, Mogens, Kvalvik, Lajla, Mengshoel, Anne Torunn, Kruczak, Katarzyna, Duarte, Raquel, Ribeiro, Nadine, Ibraim, Elmira, Kaluzhenina, Anna, Barkanova, Olga, Pesut, Dragica, Solovic, Ivan, Svetina, Petra, Souza-Galvão, Maria-Luiza de, Millet, Joan-Pau, Casas, Xavi, Vives, Montserrat, Bruchfeld, Judith, Dalemo, Paulina, Jonsson, Jerker, Aeschbacher, Katrin, Keller, Peter, Özkara, Seref, Tiberi, Simon, Chen, Christabelle, Terleeva, Yana, Dudnyk, Andrii, Health Economics and Health Technology Assessment, APH - Global Health, APH - Methodology, and Microbes in Health and Disease (MHD)

Subjects
Microbiology (medical), Evropa, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Capacity building, 610 Medicine & health, MDR-TB, Mycobacterium tuberculosis - terapija z zdravili, Microbial Sensitivity Tests, Antimicrobial resistance, Medicines, Mycobacterium tuberculosis - drug therapy, SDG 3 - Good Health and Well-being, Tuberculosis, Multidrug-Resistant, Humans, Tuberculosis, tuberkuloza - terapija z zdravili, health care costs - drug therapy, Mycobacterium tuberculosis, General Medicine, END-TB strategy, udc:616-002, tuberculosis - drug therapy, Costs, stroški zdravstvene oskrbe - terapija z zdravili, Europe, Infectious Diseases, Availability of medicines
Abstract

Objectives: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries.Methods: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries.Results: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum–maximum, €15–152), €764 (minimum–maximum, €542–15152), and €8709 (minimum–maximum, €7965–11759) in middle-income countries (n = 12) and €280 (minimum–maximum, €78–1084), €29765 (minimum–maximum, €11116–40584), and €217591 (minimum–maximum, €82827–320146) in high-income countries (n = 29), respectively.Discussion: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.

Published
2023
Full Text
View/download PDF

8. Evaluation of consensus method for the culture of Burkholderia pseudomallei in soil samples from Laos

Author

Dance, David A.B., primary, Knappik, Michael, additional, Dittrich, Sabine, additional, Davong, Viengmon, additional, Silisouk, Joy, additional, Vongsouvath, Manivanh, additional, Rattanavong, Sayaphet, additional, Pierret, Alain, additional, Newton, Paul N., additional, Amornchai, Premjit, additional, Wuthiekanun, Vanaporn, additional, Langla, Sayan, additional, and Limmathurotsakul, Direk, additional

Published
2018
Full Text
View/download PDF

9. The Utility of Blood Culture Fluid for the Molecular Diagnosis of Leptospira:A Prospective Evaluation

Author

Dittrich, Sabine, Rudgard, William E., Woods, Kate L., Silisouk, Joy, Phuklia, Weerawat, Davong, Viengmon, Vongsouvath, Manivanh, Phommasone, Koukeo, Rattanavong, Sayaphet, Knappik, Michael, Craig, Scott B., Weier, Steven L., Tulsiani, Suhella M., Dance, David A. B., Newton, Paul N., Dittrich, Sabine, Rudgard, William E., Woods, Kate L., Silisouk, Joy, Phuklia, Weerawat, Davong, Viengmon, Vongsouvath, Manivanh, Phommasone, Koukeo, Rattanavong, Sayaphet, Knappik, Michael, Craig, Scott B., Weier, Steven L., Tulsiani, Suhella M., Dance, David A. B., and Newton, Paul N.

Abstract

Leptospirosis is an important zoonosis worldwide, with infections occurring after exposure to contaminated water. Despite being a global problem, laboratory diagnosis remains difficult with culture results taking up to 3 months, serology being retrospective by nature, and polymerase chain reaction showing limited sensitivity. Leptospira have been shown to survive and multiply in blood culture media, and we hypothesized that extracting DNA from incubated blood culture fluid (BCF), followed by quantitative real-time polymerase chain reaction (qPCR) could improve the accuracy and speed of leptospira diagnosis. We assessed this retrospectively, using preincubated BCF of Leptospira spp. positive (N = 109) and negative (N = 63) febrile patients in Vientiane, Lao PDR. The final method showed promising sensitivities of 66% (95% confidence interval [CI]: 55–76) and 59% (95% CI: 49–68) compared with direct or direct and indirect testing combined, as the respective reference standards (specificities > 95%). Despite these promising diagnostic parameters, a subsequent prospective evaluation in a Lao hospital population (N = 352) showed that the sensitivity was very low (∼30%) compared with qPCR on venous blood samples. The disappointingly low sensitivity does suggest that venous blood samples are preferable for the clinical microbiology laboratory, although BCF might be an alternative if leptospirosis is only suspected postadmission after antibiotics have been used.

Published
2016

11. The Utility of Blood Culture Fluid for the Molecular Diagnosis of Leptospira: A Prospective Evaluation

Author

Dittrich, Sabine, primary, Rudgard, William E., additional, Woods, Kate L., additional, Silisouk, Joy, additional, Phuklia, Weerawat, additional, Davong, Viengmon, additional, Vongsouvath, Manivanh, additional, Phommasone, Koukeo, additional, Rattanavong, Sayaphet, additional, Knappik, Michael, additional, Craig, Scott B., additional, Weier, Steven L., additional, Tulsiani, Suhella M., additional, Dance, David A. B., additional, and Newton, Paul N., additional

Published
2016
Full Text
View/download PDF

12. Land use and soil type determine the presence of the pathogen Burkholderia pseudomallei in tropical rivers

Author

Ribolzi, Olivier, primary, Rochelle-Newall, Emma, additional, Dittrich, Sabine, additional, Auda, Yves, additional, Newton, Paul N., additional, Rattanavong, Sayaphet, additional, Knappik, Michael, additional, Soulileuth, Bounsamai, additional, Sengtaheuanghoung, Oloth, additional, Dance, David A. B., additional, and Pierret, Alain, additional

Published
2016
Full Text
View/download PDF

14. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51

Author

Eder, Susanne, primary, Dubischar-Kastner, Katrin, additional, Firbas, Christa, additional, Jelinek, Tomas, additional, Jilma, Bernd, additional, Kaltenboeck, Astrid, additional, Knappik, Michael, additional, Kollaritsch, Herwig, additional, Kundi, Michael, additional, Paulke-Korinek, Maria, additional, Schuller, Elisabeth, additional, and Klade, Christoph S., additional

Published
2011
Full Text
View/download PDF

15. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51

Author

Eder, Susanne, Dubischar-Kastner, Katrin, Firbas, Christa, Jelinek, Tomas, Jilma, Bernd, Kaltenboeck, Astrid, Knappik, Michael, Kollaritsch, Herwig, Kundi, Michael, Paulke-Korinek, Maria, Schuller, Elisabeth, and Klade, Christoph S.

Subjects
*JAPANESE encephalitis viruses, *IMMUNITY, *VACCINATION, *DRUG dosage, *IMMUNIZATION, *RANDOMIZED controlled trials, *CLINICAL medicine, *PREVENTIVE medicine
Abstract

Abstract: Introduction: IXIARO (IC51), a recently approved inactivated Japanese Encephalitis vaccine, is immunogenic and safe in a 0/28 days primary immunization schedule. Neutralizing antibody titers decline with time and booster doses are likely needed to enhance persistence of immunity. Objectives: To assess the effect of a booster dose on neutralizing JE antibody titers for up to 12 months after boostering. Methods: In this phase III trial, 198 subjects, who had received primary immunization in a preceding randomized trial, were boosted with IXIARO 15 months after the primary immunization. Neutralizing antibody titers were assessed by plaque-reduction neutralisation test, PRNT. Results: Prior to the booster dose, 69.2% (137/198) of subjects had PRNT50 titers ≥1:10. One month after the booster, the rate of subjects with PRNT50≥1:10 (recognized as a protective titer) was 100%. This rate remained high at 98.5% at 6 and 12 months; GMTs were 22.5 before the booster and 900, 487 and 361 at 1, 6 and 12 months after the booster, respectively. Conclusion: A booster dose of IXIARO at 15 months after primary immunization was highly immunogenic with GMTs >5-fold higher than those seen immediately after primary immunization, and remained at high levels for at least 12 months after the booster. NCT00595309. [Copyright &y& Elsevier]

Published
2011
Full Text
View/download PDF

16. [Ill tropical traveler returning home].

Author

Knappik M and Jelinek T

Subjects
Adult, Asia, Southeastern, Diagnosis, Differential, Humans, Leukocyte Count, Male, Platelet Count, Diarrhea etiology, Exanthema etiology, Fatigue etiology, Fever of Unknown Origin etiology, Headache etiology, Severe Dengue diagnosis, Travel, Tropical Medicine
Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results